GLP-1s and fatty liver: what the trials measured

Reviewed 21 sourcesPublished by PepVault

Wegovy is approved for MASH, the inflamed fatty liver. What semaglutide, tirzepatide, survodutide and retatrutide did to liver fat and scarring, side by side.

Grey-haired man in a white linen shirt pulls a grey carry-on along a palm-lined seaside promenade
Last reviewed
Sources
21
Questions
7
Compounds
6

The short answer

One GLP-1 is approved for fatty liver. Since August 15, 2025, Wegovy (semaglutide 2.4 mg) has FDA accelerated approval for MASH, the inflamed form, in adults with moderate to advanced scarring and no cirrhosis. In its trial, MASH cleared in 63% of people against 34% on placebo at 72 weeks. Tirzepatide, survodutide and retatrutide cut liver fat sharply in trials but are not approved for it.

  • Wegovy (semaglutide 2.4 mg) is the one GLP-1 approved for MASH, since August 15, 2025, for scarring at stage F2 or F3 without cirrhosis.
  • In biopsy trials, MASH cleared in 63% on semaglutide and up to 62% on tirzepatide, against 34% and 10% on placebo.
  • Retatrutide cut liver fat by up to 82% in 24 weeks; survodutide cut it by 30% or more in 84% of people.
  • No drug has yet shown fewer cirrhosis cases or liver deaths; those trials are still running.

Every number checked at its primary source · · 21 sources · How we research

Evidence: Phase 3 biopsy trial for semaglutide (the basis of Wegovy's accelerated approval); phase 2 biopsy trials for tirzepatide, survodutide and efinopegdutide; MRI-only trials for retatrutide and survodutide's phase 3; no drug yet shown to prevent cirrhosis or liver deaths.

Grey-haired man in a white linen shirt pulls a grey carry-on along a palm-lined seaside promenade

Is any GLP-1 approved for fatty liver?

One, as of November 2026. On August 15, 2025 the FDA approved Wegovy injection for noncirrhotic MASH with moderate to advanced liver fibrosis (scarring at stage F2 or F3) in adults2. It is an accelerated approval: the FDA accepted improvements seen in liver biopsies as a sign likely to predict real benefit, and Novo Nordisk must finish a 240-week trial that counts what matters most, progression to cirrhosis, liver failure events, transplants and deaths2. The current label, published June 2026, keeps the indication with that condition attached1. The UK's medicines regulator followed on July 3, 2026 with a conditional approval for the same group17.

The approval belongs to Wegovy alone. Wegovy tablets carry no MASH use on the same label1. Ozempic is the same molecule, but its label carries none, and neither do Zepbound or Mounjaro (tirzepatide), whose labels were revised in August 2026192021. The first drug of any kind approved for MASH was not a GLP-1: Rezdiffra (resmetirom), a daily pill, on March 14, 202410.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs your weekly shot and keeps your weigh-ins on one chart, and its Bloodwork page stores liver results such as ALT, AST and GGT by date, so the numbers your doctor follows sit in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What do MASLD, MASH and NAFLD mean?

They are the old and new names for the same diseases. In 2023, 236 liver specialists and patient advocates from 56 countries voted to drop "nonalcoholic fatty liver disease" (NAFLD), a name defined by what it was not and one most panelists found stigmatizing12. Fat building up in the liver is now MASLD, metabolic dysfunction-associated steatotic liver disease, and it needs at least one of five heart-and-metabolism risk factors such as excess weight or waist size, or high blood pressure12. Its inflamed, damaging form, once NASH, is now MASH: metabolic dysfunction-associated steatohepatitis. People with MASLD who also drink more than a set weekly amount fall into a new middle group, MetALD12.

Scarring is graded from F0 (none) to F4 (cirrhosis)9. A healthy liver holds under 5% fat5. Papers before 2023 say NAFLD and NASH; the trials below are the same diseases under either name. PepVault's glossary explains MASH at pepvault.app/glossary/mash, and pepvault.app/conditions/fatty-liver-disease gathers the liver studies we cover.

What did each drug do to liver fat and scarring?

Two kinds of result appear in these trials. A scan called MRI-PDFF measures the share of the liver that is fat. A biopsy, a thin needle sample of liver read under a microscope, shows whether the inflammation cleared ("MASH resolved") and whether the scarring fell by at least one stage. The table gives each drug's result against its own placebo group. Every row is a separate trial, in different people over different lengths of time, so read each drug against its placebo, not against the row above.

Drug, trialWho and how longLiver fat on MRIMASH resolved, scarring not worseScarring down 1+ stage
Semaglutide 2.4 mg weekly, ESSENCE (phase 3)800 with MASH, F2–F3; 72 weeksNot a main result62.9% vs 34.3%36.8% vs 22.4%
Tirzepatide 5, 10, 15 mg weekly, SYNERGY-NASH (phase 2)190 with MASH, F2–F3; 52 weeksNot a main result44%, 56%, 62% vs 10%55%, 51%, 51% vs 30%
Tirzepatide 10 and 15 mg, SURPASS-3 MRI (phase 3 substudy)296 with type 2 diabetes and likely fatty liver; 52 weeks−8.1 points vs −3.4 on insulin (from 15.7%)No biopsyNo biopsy
Survodutide 2.4, 4.8, 6.0 mg weekly (phase 2)293 with MASH, F1–F3; 48 weeks30%+ drop in 63%, 67%, 57% vs 14%MASH improved (not resolved): 47%, 62%, 43% vs 14%34%, 36%, 34% vs 22%
Survodutide 6.0 mg weekly, SYNCHRONIZE-MASLD (phase 3)216 with obesity and at-risk MASLD; 48 weeks30%+ drop in 84.2% vs 24.3%No biopsy endpointNo biopsy endpoint
Retatrutide 1, 4, 8, 12 mg weekly (phase 2 substudy)98 with MASLD and 10%+ liver fat; 24 weeks−42.9%, −57.0%, −81.4%, −82.4% vs +0.3%No biopsyNo biopsy
Efinopegdutide 4, 7, 10 mg weekly (phase 2b)381 with MASH, F2–F3; 52 weeksNot a main result56%, 63%, 61% vs 13%43%, 52%, 34% vs 21%
Resmetirom 80 or 100 mg daily pill, MAESTRO-NASH (phase 3; not a GLP-1)966 with MASH, F1B–F3; 52 weeksNot a main result25.9%, 29.9% vs 9.7%24.2%, 25.9% vs 14.2%

Sources by row: ESSENCE3, SYNERGY-NASH4, SURPASS-3 MRI13 (an open-label comparison with insulin degludec, not placebo), survodutide phase 27, SYNCHRONIZE-MASLD6 (efficacy estimand), retatrutide5 (main result at 24 weeks), efinopegdutide8, MAESTRO-NASH9. The trials' doses are reported as the trials gave them, not as a dose for anyone.

Two numbers stand out. Retatrutide, which acts on three hormone receptors, took liver fat into the normal range, under 5%, in 79% of people on 8 mg and 86% on 12 mg at 24 weeks, against none on placebo5. And semaglutide is the only GLP-1 so far with a phase 3 biopsy result, the kind regulators approve on3. An older, smaller trial of daily liraglutide (Victoza's molecule) cleared MASH in 9 of 23 people against 2 of 22 on placebo over 48 weeks16. Trial pages such as pepvault.app/research/survodutide-synchronize-masld-2026 give each study in full.

Why does liver fat fall so far on these drugs?

Mostly through weight. The liver stores the fat the body cannot use elsewhere, and losing body weight drains it. In a 52-week study of 293 people with biopsy-proven NASH who changed only diet and exercise, everyone who lost 10% or more of their weight saw their liver score improve, 90% saw NASH resolve and 45% saw scarring go back14. GLP-1 drugs reach that weight loss more often: people in ESSENCE lost 10.5% of their weight against 2.0% on placebo3. Wegovy's label says the mechanism in MASH is not fully understood and may run through weight loss and other pathways1.

The newer drugs add a second lever. Glucagon, the hormone that tells the liver to release stored energy, acts on the liver directly. Survodutide and efinopegdutide act on both the GLP-1 and glucagon receptors, and retatrutide on GIP as well; these are called dual and triple agonists. The retatrutide authors write, drawing on animal studies, that glucagon may lower liver fat by making the liver burn more fat and build less; in their trial a blood marker of fat burning rose two- to threefold on 4 mg and above. They also cite an earlier trial in which efinopegdutide cut liver fat more than semaglutide at the same weight loss, a sign of a drop beyond what weight loss alone would give5. No head-to-head trial has yet tested a dual agonist against semaglutide for MASH; the efinopegdutide trial gave open-label semaglutide 2.4 mg to one arm as a reference, and 53% of that group cleared MASH8.

Is less liver fat the same as a healthier liver?

It is an early sign, not the finish line. Fat on an MRI can fall within months (most of retatrutide's drop came in the first 24 weeks5), while scarring is what decides whether a liver goes on to cirrhosis. That is why the approvals rest on biopsies, and why both Wegovy and Rezdiffra carry a condition: the long trials still have to show fewer cases of cirrhosis, liver failure and death211. As of November 2026, no drug for MASH has published that outcome.

The outcome trials under way, as of November 2026, include Lilly's SYNERGY-Outcomes, which tests tirzepatide and retatrutide against placebo in about 4,500 people for cirrhosis, liver complications and deaths (NCT07165028), and Boehringer Ingelheim's LIVERAGE trials of survodutide in fibrosis and in cirrhosis (NCT06632444, NCT06632457), all recruiting.

PepVault logs your weekly shot and keeps your weigh-ins on one chart, and its Bloodwork page stores liver results such as ALT, AST and GGT by date, so the numbers your doctor follows sit in one place. Track your weight in PepVault

What about cirrhosis?

Here the GLP-1 data are thin. In a phase 2 trial of 71 people with MASH and compensated cirrhosis (scarred, but the liver still working), semaglutide 2.4 mg did no better than placebo over 48 weeks: scarring improved in 11% against 29%, a gap that was not statistically significant, and MASH resolution did not differ either15. Both approved MASH drugs are labeled for livers without cirrhosis, and Rezdiffra's label says to avoid it in decompensated cirrhosis, the stage where the liver begins to fail111. Only 7% of people in Wegovy's MASH trial had a BMI under 25, and its label says information on that group is limited1.

When to get help Yellowing of the skin or the whites of the eyes, or a belly that swells with fluid, can be a sign of advanced liver disease and is a reason to see your doctor soon18.

How does Wegovy compare with Rezdiffra for MASH?

They work in different ways. Rezdiffra is a daily tablet that switches on a thyroid hormone receptor found in the liver (THR-beta), dosed by body weight on its label, 80 mg under 100 kg and 100 mg at 100 kg or more11. Beyond its liver results in the table above, it lowered LDL cholesterol by 13.6% and 16.3% at 24 weeks in its phase 3 trial9. Wegovy is a weekly shot whose effect on MASH runs partly through weight loss, with a 63% against 34% MASH result in its own trial1. The two trials enrolled different people, so their numbers are not a head-to-head comparison.

Whether a liver needs treatment, and which drug fits, is your doctor's decision, usually a liver specialist's, made from your blood tests, scans or a biopsy, your weight, and your other conditions. What this page shows is what each drug was measured to do.

Side effects in the MASH trials looked like each drug's other uses. Wegovy's label says the most common reactions in its MASH trial matched its weight-loss trials, led by nausea, diarrhea and other stomach effects1; for tirzepatide and survodutide too, the most common were gut-related, mostly mild to moderate47. The label also lists fractures in the MASH trial in 4.4% of people on Wegovy against 3.3% on placebo1. The full list is at pepvault.app/peptides/semaglutide/side-effects.

Commonly reported: people on a GLP-1 for weight often say a routine blood test showed their liver enzymes, usually ALT, back in the normal range, or that a follow-up scan showed less fat. These are users' own accounts, not trial measures.

Track it in the app

Sources

  1. Wegovy (semaglutide) injection and tablets, prescribing information (§1, §6.1, §12.1, §14.4 and Table 21). Novo Nordisk. DailyMed, published June 30, 2026. dailymed.nlm.nih.gov
  2. US FDA. Approval letter, NDA 215256/S-024 (Wegovy), accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis. August 15, 2025. accessdata.fda.gov
  3. Sanyal AJ et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089-2099. PubMed 40305708
  4. Loomba R et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4):299-310. PubMed 38856224
  5. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PubMed 38858523
  6. Kaplan LM et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948-2958. PubMed 42252333
  7. Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311-319. PubMed 38847460
  8. Lawitz E et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026 (online November 9). PubMed 43003105
  9. Harrison SA et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. PubMed 38324483
  10. US FDA. FDA approves first treatment for patients with liver scarring due to fatty liver disease. Press announcement, March 14, 2024. fda.gov
  11. Rezdiffra (resmetirom) tablets, prescribing information. Madrigal Pharmaceuticals. DailyMed, published August 5, 2026. dailymed.nlm.nih.gov
  12. Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PubMed 37363821
  13. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Lancet Diabetes Endocrinol. 2022;10(6):393-406. PubMed 35468325
  14. Vilar-Gomez E et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. PubMed 25865049
  15. Loomba R et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. PubMed 36934740
  16. Armstrong MJ et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. PubMed 26608256
  17. Medicines and Healthcare products Regulatory Agency (UK). Semaglutide (Wegovy) approved to treat form of liver disease. July 3, 2026. gov.uk
  18. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Symptoms and causes of cirrhosis. Reviewed June 2023. niddk.nih.gov
  19. Ozempic (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, effective June 2026. dailymed.nlm.nih.gov
  20. Zepbound (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, revised August 2026. dailymed.nlm.nih.gov
  21. Mounjaro (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, revised August 2026. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo